Abbott Laboratories (ABT) shares are trading at a discount to the Zacks Medical Products industry. Its trailing 12-month price-to-book value of 4.91X is significantly lower than the industry average of 7.64X and the benchmark’s average of 8.77.The stock also remains attractively valued compared to its peers like Boston Scientific (BSX) with a P/B of 6.47X and Stryker (SYK) with a P/B of 6.72.A low P/B compared to the industry average and competitors can present a buying opportunity for value investors on th ...

Michael (Mike) Dion is an FP&A, Corporate Finance, and Small Business expert who spent the last 12 years working in the Fortune 100, building a startup's finance and accounting department, advising small businesses, and guiding non-profit organizations as a board member. He has finance experience across multiple industries, including Telecom, Media and Entertainment, Hospitality, and Construction. He founded F9 Finance, a website that helps Finance professionals accelerate their careers; and simplifies Fina ...

Abbott (ABT) ended the recent trading session at $113.04, demonstrating a -0.69% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 0.55%. Elsewhere, the Dow lost 0.06%, while the tech-heavy Nasdaq added 1.24%.Market participants will be closely following the financial results of Abbott in its upcoming release. The company plans to announce its earnings on January 22, 2025. The company is forecasted to report an EPS of $1.34, showcasing a 12.61% upwa ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Abbott (ABT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Abbott is a member of our Medical group, which includes 1011 different companies and currently sits at # ...

The MedTech industry has demonstrated resilience and growth throughout 2024 despite enduring persistent challenges such as supply chain disruptions, regulatory hurdles, and the need to adapt to rapidly advancing technologies. Notably, the Dow Jones U.S. Select Medical Equipment Index grew 10% during 2024, reflecting the sector's ability to adapt and innovate.Factors Likely to Drive Growth for the MedTech Space in 2025In 2025, the MedTech industry is likely to experience growth driven by technological advanc ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of BTAFF, CVX, EOG, HSY, KO, PEP, PFE, PG, RBGPF, UNLYF, XOM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. The contents of this article, my previous articles, and my comments are for informational ...

A few different elements can make a stock a no-brainer buy. The company could be the leader in its market, or well diversified across various markets. In any case, it should have a solid track record of earnings growth and promising long-term prospects. It should be the sort of company that you can add to your portfolio, then sit back and relax -- because you're confident that this player will excel over time.It's the kind of stock you'll want to buy now and hold on to for the long haul, and by this, I mean ...

公司业务发展 - 公司多元化业务组合在2025年有望继续保持增长势头 [1] - 公司在生物类似药领域取得战略进展 计划在2025年完成首轮商业化 生物类似药是品牌仿制药市场中增长最快的领域 [2] - 糖尿病护理业务受益于旗舰产品FreeStyle Libre的销售增长 该产品在全球连续血糖监测系统中处于领先地位 [7] - 诊断业务在2024年第三季度占总收入的22.6% 公司在即时检测领域占据重要地位 并成功扩展测试菜单 [8] - 2024年第三季度 糖尿病护理业务中连续血糖监测系统销售额超过16亿美元 同比增长21% [11] 财务表现 - 2024年第三季度 产品销售成本（不包括摊销费用）同比增长2.1% 销售、一般和行政费用同比增长6.3% [9] - 2024年第三季度 外汇对公司销售产生了2.5%的不利影响 [4] 行业环境 - 全球宏观经济环境恶化 导致对多个医疗技术产品的需求减少 销售下降 产品价格降低 同时商品成本和运营费用增加 [13] - 过去三个月 公司股价上涨2.6% 而行业整体下跌2.2% [12] 其他公司表现 - Haemonetics公司2025财年每股收益预估保持在4.59美元 过去一年股价下跌3.6% 而行业增长17.3% [6] - Penumbra公司过去一年股价上涨10.5% 2024年每股收益预估在过去30天内上涨0.7%至2.81美元 [14] - ResMed公司2025财年每股收益预估在过去30天内上涨2.5%至1.61美元 过去一年股价飙升113.5% [15]

Like all its peers, Abbott Laboratories (ABT) faced the industrywide challenges of margin pressure through 2024, stemming from growing inflation, labor shortages and supply chain disruptions, which increased operational costs. However, the company’s ability to pivot and deliver solid results in key areas underscores its resilience and strategic acumen. The company is poised to conclude 2024 on a strong and optimistic trajectory, focusing largely on strategic investments and operational efficiency.Abbott is ...

公司表现 - 公司股票最新收盘价为11431美元较前一交易日上涨007% [1] - 公司股票在过去一个月内下跌3%表现优于医疗行业的38%跌幅但落后于标普500的034%涨幅 [8] - 公司预计在即将发布的财报中每股收益为134美元同比增长1261%营收预计为1102亿美元同比增长764% [3] - 公司全年预计每股收益为467美元同比增长518%营收预计为420亿美元同比增长471% [9] 估值指标 - 公司当前远期市盈率为2445低于行业平均的2512 [5] - 公司当前PEG比率为269高于行业平均的229 [11] 行业表现 - 医疗产品行业在Zacks行业排名中位列124属于所有250多个行业中的前50% [6] - Zacks行业排名显示前50%的行业表现优于后50%的行业表现比例为2:1 [12] 分析师评级 - 公司目前Zacks评级为2（买入） [10] - 分析师对公司盈利预期的调整反映了对公司业务和盈利能力的乐观态度 [2]